ACRS
Aclaris Therapeutics Inc
4.40$
-16.2%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | +499.6% | -58.1% | +53.3% | +4.3% | +340.1% | +5.0% | -40.1% | -58.2% | |
| – | – | – | +33.3% | +905.8% | +467.5% | -40.8% | +26.6% | -8.2% | +153.8% | +51.2% | -84.6% | -25.1% | |
| – | – | – | – | – | +580.9% | -94.7% | +684.3% | +51.8% | +768.8% | -26.0% | +21.0% | -64.0% | |
| – | +86.6% | +135.7% | +118.2% | +18.9% | +58.4% | +3.0% | -51.1% | +38.1% | +77.6% | +26.4% | -65.9% | +56.7% | |
| – | +14.5% | +163.0% | +183.2% | +119.4% | -16.5% | -1.8% | -24.4% | +15.0% | +6.4% | +23.7% | -28.6% | -1.0% | |
| – | +62.3% | +142.2% | +135.0% | +50.1% | +90.2% | -33.1% | -43.6% | +75.6% | +17.3% | +2.7% | +42.8% | -48.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | +2,153.7% | -79.9% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | +995.2% | -100.6% | – | -92.5% | -120.9% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.